ABSTRACT

Introduction

A vaccine introduction process should be systematic and transparent and take into account many factors, including cost-effectiveness evidence. This study aimed to assess quantity, characteristic, and quality of economic evaluation (EE) studies on vaccines performed in Middle East and North Africa (MENA) countries.

Areas covered

PubMed and Scopus electronic databases were searched since inception to December 2019 to identify published EE studies of vaccines, which were conducted in the 26 MENA countries. Methodological quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.

Expert opinion

Of the 616 studies identified, 46 were included in the review. Most studies (65%) were conducted in Iran, Israel, and Turkey. The most commonly evaluated vaccines were rotavirus vaccine (n = 15; 33%), human Papillomavirus vaccine (n = 8; 17%), and pneumococcal vaccine (n = 7; 15%). We classified 5 (11%), 27 (59%), 12 (26%), and 2 (4%) studies as excellent, good, moderate, and poor quality, respectively. There were limited cost-effectiveness evidences in the region. It is imperative to have local guidelines on good practice and reporting, availability of local data, and funding sources to improve quantity and quality of EE studies of vaccines in the region, thereby, facilitating transparent and consistent decision-making processes.

中文翻译：

---

对中东和北非国家疫苗经济评估的系统评价：现有证据是否足以支持政策决策？

摘要

介绍

疫苗引入过程应该是系统的和透明的，并考虑到许多因素，包括成本效益证据。本研究旨在评估在中东和北非 (MENA) 国家开展的疫苗经济评估 (EE) 研究的数量、特征和质量。

涵盖的领域

自成立至 2019 年 12 月，对 PubMed 和 Scopus 电子数据库进行了搜索，以确定已在 26 个中东和北非国家进行的已发表的疫苗 EE 研究。使用综合健康经济评估报告标准（CHEERS）清单评估纳入研究的方法学质量。

专家意见

在确定的 616 项研究中，有 46 项被纳入评价。大多数研究（65%）是在伊朗、以色列和土耳其进行的。最常评估的疫苗是轮状病毒疫苗（n = 15；33%）、人乳头瘤病毒疫苗（n = 8；17%）和肺炎球菌疫苗（n = 7；15%）。我们将 5 项 (11%)、27 项 (59%)、12 项 (26%) 和 2 项 (4%) 研究分别归为优质、良好、中等和差质量。该地区的成本效益证据有限。必须有关于良好实践和报告、当地数据可用性和资金来源的当地指南，以提高该地区疫苗 EE 研究的数量和质量，从而促进透明和一致的决策过程。